March 21, 2025
Context Therapeutics Reports Full Year 2024 Operating and Financial Results
CTIM-76 first patient dosed in January 2025 Cash and cash equivalents of $94.4 million as of December 31, 2024 Company…
Pharmaceuticals, Biotechnology and Life Sciences
CTIM-76 first patient dosed in January 2025 Cash and cash equivalents of $94.4 million as of December 31, 2024 Company…
Data evaluating safety and early signals of efficacy including updated local PFS from the completed dose escalation part of a…
Erick J. Lucera Erick J. Lucera, Chief Financial Officer (CFO) of Dyne Therapeutics – Proven financial leader brings decades of…
MALVERN, Pa., March 20, 2025 (GLOBE NEWSWIRE) — TELA Bio, Inc. (“TELA Bio”), a commercial-stage medical technology company focused on…
– Four development candidates in clinical studies with data anticipated this year, continuing rapid progress of antiviral pipeline – –…
VCAR33 clinical data update planned for first half of 2025 and trem-cel + Mylotarg clinical data update planned for second…
– Reported positive data updates from its ongoing Phase 2a trial of lead program IMM-1-104, including encouraging responses in combination…
Dose expansion in Phase 1 CARDINAL trial of TERN-701 for chronic myeloid leukemia (CML) expected to initiate in 2Q25 with…
– Announced Positive Outcome of Interim Analysis for its Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid…
YARDLEY, Pa., March 19, 2025 (GLOBE NEWSWIRE) — Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose…